FDA Drug Recalls

Recalls / Class II

Class IID-0450-2025

Product

Carvedilol Tablets USP 12.5 mg, 500-Count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Manufactured for Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC: 68462-164-05

Brand name
Carvedilol
Generic name
Carvedilol
Active ingredient
Carvedilol
Route
Oral
NDCs
68462-162, 68462-163, 68462-164, 68462-165
FDA application
ANDA078251
Affected lot / code info
Lot, Exp: Lots 19231899, 19231922, 19231927, 19231967, 19231979, Exp Apr-25; Lots 19232226, 19232234, 19232265, 1923227,1 Exp May-25; Lots 19232758, 19232759, 19232762, 19232788, Exp Jun-25

Why it was recalled

CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit

Recalling firm

Firm
Glenmark Pharmaceuticals Inc., USA
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
750 Corporate Dr, N/A, Mahwah, New Jersey 07430-2009

Distribution

Quantity
84,048 bottles
Distribution pattern
U.S. Nationwide

Timeline

Recall initiated
2025-02-28
FDA classified
2025-05-28
Posted by FDA
2025-06-04
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0450-2025. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Carvedilol · FDA Drug Recalls